[A case of long-term survival due to combined modality therapy for liver metastasis of colon cancer].

Hirofumi Hasegawa, Takashi Hashimoto, Toshihiko Nakamura, Masaru Kitagawa, Kensuke Kudo, Fumihiro Shoji, Akira Kabashima, Seiichi Teramoto, Masayuki Kitamura

Research output: Contribution to journalArticle

Abstract

The patient was a 68-year-old man. Because sigmoid colon cancer and metastatic liver cancer was diagnosed in August 2009, an indwelling central venous port and sigmoid colon resection were implemented. The metastatic liver cancer was a huge tumor occupying the right hepatic lobe and caudate lobe. In consideration of the risk associated with the resection and the possibility of early recurrence, the postoperative chemotherapy was selected. He underwent 9 courses of bevacizumab (Bev)+FOLFOX. The tumor was observed to reduce but continued to occupy the right lobe and caudate lobe. At this point, the surgical treatment was selected because the tumor has been shrunk and there is no appearance of new metastases. In order to preserve residual liver function, he underwent percutaneous transhepatic portal embolization and then resection of the right lobe of the liver in February 2010. Although the Bev+FOLFOX treatment was started again after surgery as adjuvant chemotherapy, the metastatic liver cancer recurred in the remnant liver in August 2010. Because it was about 6 months from the first recurrence of liver resection, we decided to continue chemotherapy immediately without resection. However, the chemotherapy was insufficient to shrink the tumor, which increased because it was present at 3 locations in the liver. Therefore, partial hepatectomy at the 3 locations with positron-emission tomography was performed in February 2011. Since then, chemotherapy has not been performed in patients, and there is no recurrence as of March 2012. In the guideline for the treatment of liver metastasis of colorectal cancer, even though chemotherapy is currently developed, the surgical procedure is recommended for patients who are responsive to local therapy. If the cancer recur immediately after resection, it is difficult to decide whether to re-resect. We report the case in which the tumor-free status can be observed as a result of a combination of systemic chemotherapy and local therapy.

Original languageEnglish
Pages (from-to)2234-2236
Number of pages3
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume39
Issue number12
Publication statusPublished - Jan 1 2012

Fingerprint

Combined Modality Therapy
Colonic Neoplasms
Neoplasm Metastasis
Liver Neoplasms
Survival
Liver
Drug Therapy
Neoplasms
Recurrence
Sigmoid Neoplasms
Therapeutics
Hepatectomy
Sigmoid Colon
Adjuvant Chemotherapy
Combination Drug Therapy
Positron-Emission Tomography
Colorectal Neoplasms
Guidelines

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hasegawa, H., Hashimoto, T., Nakamura, T., Kitagawa, M., Kudo, K., Shoji, F., ... Kitamura, M. (2012). [A case of long-term survival due to combined modality therapy for liver metastasis of colon cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 39(12), 2234-2236.

[A case of long-term survival due to combined modality therapy for liver metastasis of colon cancer]. / Hasegawa, Hirofumi; Hashimoto, Takashi; Nakamura, Toshihiko; Kitagawa, Masaru; Kudo, Kensuke; Shoji, Fumihiro; Kabashima, Akira; Teramoto, Seiichi; Kitamura, Masayuki.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 39, No. 12, 01.01.2012, p. 2234-2236.

Research output: Contribution to journalArticle

Hasegawa, H, Hashimoto, T, Nakamura, T, Kitagawa, M, Kudo, K, Shoji, F, Kabashima, A, Teramoto, S & Kitamura, M 2012, '[A case of long-term survival due to combined modality therapy for liver metastasis of colon cancer].', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 39, no. 12, pp. 2234-2236.
Hasegawa H, Hashimoto T, Nakamura T, Kitagawa M, Kudo K, Shoji F et al. [A case of long-term survival due to combined modality therapy for liver metastasis of colon cancer]. Gan to kagaku ryoho. Cancer & chemotherapy. 2012 Jan 1;39(12):2234-2236.
Hasegawa, Hirofumi ; Hashimoto, Takashi ; Nakamura, Toshihiko ; Kitagawa, Masaru ; Kudo, Kensuke ; Shoji, Fumihiro ; Kabashima, Akira ; Teramoto, Seiichi ; Kitamura, Masayuki. / [A case of long-term survival due to combined modality therapy for liver metastasis of colon cancer]. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2012 ; Vol. 39, No. 12. pp. 2234-2236.
@article{6463fb29fb084e85898afb863935124d,
title = "[A case of long-term survival due to combined modality therapy for liver metastasis of colon cancer].",
abstract = "The patient was a 68-year-old man. Because sigmoid colon cancer and metastatic liver cancer was diagnosed in August 2009, an indwelling central venous port and sigmoid colon resection were implemented. The metastatic liver cancer was a huge tumor occupying the right hepatic lobe and caudate lobe. In consideration of the risk associated with the resection and the possibility of early recurrence, the postoperative chemotherapy was selected. He underwent 9 courses of bevacizumab (Bev)+FOLFOX. The tumor was observed to reduce but continued to occupy the right lobe and caudate lobe. At this point, the surgical treatment was selected because the tumor has been shrunk and there is no appearance of new metastases. In order to preserve residual liver function, he underwent percutaneous transhepatic portal embolization and then resection of the right lobe of the liver in February 2010. Although the Bev+FOLFOX treatment was started again after surgery as adjuvant chemotherapy, the metastatic liver cancer recurred in the remnant liver in August 2010. Because it was about 6 months from the first recurrence of liver resection, we decided to continue chemotherapy immediately without resection. However, the chemotherapy was insufficient to shrink the tumor, which increased because it was present at 3 locations in the liver. Therefore, partial hepatectomy at the 3 locations with positron-emission tomography was performed in February 2011. Since then, chemotherapy has not been performed in patients, and there is no recurrence as of March 2012. In the guideline for the treatment of liver metastasis of colorectal cancer, even though chemotherapy is currently developed, the surgical procedure is recommended for patients who are responsive to local therapy. If the cancer recur immediately after resection, it is difficult to decide whether to re-resect. We report the case in which the tumor-free status can be observed as a result of a combination of systemic chemotherapy and local therapy.",
author = "Hirofumi Hasegawa and Takashi Hashimoto and Toshihiko Nakamura and Masaru Kitagawa and Kensuke Kudo and Fumihiro Shoji and Akira Kabashima and Seiichi Teramoto and Masayuki Kitamura",
year = "2012",
month = "1",
day = "1",
language = "English",
volume = "39",
pages = "2234--2236",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "12",

}

TY - JOUR

T1 - [A case of long-term survival due to combined modality therapy for liver metastasis of colon cancer].

AU - Hasegawa, Hirofumi

AU - Hashimoto, Takashi

AU - Nakamura, Toshihiko

AU - Kitagawa, Masaru

AU - Kudo, Kensuke

AU - Shoji, Fumihiro

AU - Kabashima, Akira

AU - Teramoto, Seiichi

AU - Kitamura, Masayuki

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The patient was a 68-year-old man. Because sigmoid colon cancer and metastatic liver cancer was diagnosed in August 2009, an indwelling central venous port and sigmoid colon resection were implemented. The metastatic liver cancer was a huge tumor occupying the right hepatic lobe and caudate lobe. In consideration of the risk associated with the resection and the possibility of early recurrence, the postoperative chemotherapy was selected. He underwent 9 courses of bevacizumab (Bev)+FOLFOX. The tumor was observed to reduce but continued to occupy the right lobe and caudate lobe. At this point, the surgical treatment was selected because the tumor has been shrunk and there is no appearance of new metastases. In order to preserve residual liver function, he underwent percutaneous transhepatic portal embolization and then resection of the right lobe of the liver in February 2010. Although the Bev+FOLFOX treatment was started again after surgery as adjuvant chemotherapy, the metastatic liver cancer recurred in the remnant liver in August 2010. Because it was about 6 months from the first recurrence of liver resection, we decided to continue chemotherapy immediately without resection. However, the chemotherapy was insufficient to shrink the tumor, which increased because it was present at 3 locations in the liver. Therefore, partial hepatectomy at the 3 locations with positron-emission tomography was performed in February 2011. Since then, chemotherapy has not been performed in patients, and there is no recurrence as of March 2012. In the guideline for the treatment of liver metastasis of colorectal cancer, even though chemotherapy is currently developed, the surgical procedure is recommended for patients who are responsive to local therapy. If the cancer recur immediately after resection, it is difficult to decide whether to re-resect. We report the case in which the tumor-free status can be observed as a result of a combination of systemic chemotherapy and local therapy.

AB - The patient was a 68-year-old man. Because sigmoid colon cancer and metastatic liver cancer was diagnosed in August 2009, an indwelling central venous port and sigmoid colon resection were implemented. The metastatic liver cancer was a huge tumor occupying the right hepatic lobe and caudate lobe. In consideration of the risk associated with the resection and the possibility of early recurrence, the postoperative chemotherapy was selected. He underwent 9 courses of bevacizumab (Bev)+FOLFOX. The tumor was observed to reduce but continued to occupy the right lobe and caudate lobe. At this point, the surgical treatment was selected because the tumor has been shrunk and there is no appearance of new metastases. In order to preserve residual liver function, he underwent percutaneous transhepatic portal embolization and then resection of the right lobe of the liver in February 2010. Although the Bev+FOLFOX treatment was started again after surgery as adjuvant chemotherapy, the metastatic liver cancer recurred in the remnant liver in August 2010. Because it was about 6 months from the first recurrence of liver resection, we decided to continue chemotherapy immediately without resection. However, the chemotherapy was insufficient to shrink the tumor, which increased because it was present at 3 locations in the liver. Therefore, partial hepatectomy at the 3 locations with positron-emission tomography was performed in February 2011. Since then, chemotherapy has not been performed in patients, and there is no recurrence as of March 2012. In the guideline for the treatment of liver metastasis of colorectal cancer, even though chemotherapy is currently developed, the surgical procedure is recommended for patients who are responsive to local therapy. If the cancer recur immediately after resection, it is difficult to decide whether to re-resect. We report the case in which the tumor-free status can be observed as a result of a combination of systemic chemotherapy and local therapy.

UR - http://www.scopus.com/inward/record.url?scp=84875924625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875924625&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 2234

EP - 2236

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 12

ER -